-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Benzinga·08/14/2026 10:12:14
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.